Ann Dermatol. 2020 Aug;32(4):337-342. English.
Published online Jun 30, 2020.
Copyright © 2020 The Korean Dermatological Association and The Korean Society for Investigative Dermatology
Brief Communication

A Retrospective Clinicopathologic Study of Korean Patients with Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified at a Single Tertiary Center

Ji-Hye Park, YoungHwan Choi, Hyun Jeong Byun, Se Jin Oh, Jong Hee Lee and Dong-Youn Lee
    • Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Received April 25, 2019; Revised September 15, 2019; Accepted September 18, 2019.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dear Editor:

Cutaneous peripheral T-cell lymphoma, not otherwise specified (cPTCL-NOS), is a rare disease either originating from skin or having secondary skin involvement1, 2. In the past, cPTCL-NOS was categorized into the CD30-medium/large pleomorphic T-cell lymphoma group but now is defined as a heterogeneous category of nodal and extranodal neoplasms that cannot be classified into any other specific entities according to the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008)3. Therefore, it is a diagnosis of exclusion, and the nature of the disease is not yet clear. To better understand and define cPTCL-NOS, we assessed the clinical and histopathological features of the disease and analyzed prognostic factors.

We retrospectively reviewed the medical records, photographs, laboratory data, and histopathology of patients diagnosed with cPTCL-NOS by a hematopathologist at Samsung Medical Center from January 2008 to June 2017. We analyzed 13 patients and 15 biopsy specimens (Table 1, 2). This study was approved by the Institutional Review Board of Samsung Medical Center (SMC 2018-01-119). Skin biopsies were performed at two sites in two patients (cases #12 and #13). The prognostic index for T-cell lymphoma (PIT) was calculated from 0 to 4 by age, performance status, lactic dehydrogenase level, and bone marrow (BM) involvement. Treatment outcomes were determined as overall survival (OS) and disease-specific death and prognostic factor comparisons were performed by univariable analysis with a Cox proportional hazards regression model. The male-to-female ratio was 1.17 and the median age at diagnosis was 52 years (range, 23~81 years). Ten patients showed systemic PTCL-NOS with concurrent skin involvement and all patients, except case 7, were nodal lymphoma. Three patients showed primary cPTCL-NOS but case 2 showed BM involvement 6 months after diagnosis. Twelve patients were observed to have skin lesions and one had lymph node (LN) enlargement at first presentation. More than half the patients (61.54%) showed generalized skin involvement, 46.15% presented with nodules, and 38.46% had B symptoms. Only one patient (case #6) was in the high-risk group (PIT=4) and died 12 months after diagnosis. The histopathological and immunohistochemical features (Table 2) of all biopsy specimens except one (case #10) showed small-to-medium-sized tumor cell infiltrations. Significant atypia was observed in six samples (40.0%). Twelve specimens were positive for CD3 (100%, 12/12) and CD4 (92.3%, 12/13). T-cell receptor (TCR) gene rearrangement showed monoclonality (100%, 6/6). Six samples were positive for CD30 (66.7%, 6/9) and one was associated with Epstein-Barr virus (16.7%, 1/6). The median OS was longer than 17 months after diagnosis. Comparisons of prognostic factors (age, sex, primary vs. secondary skin involvement, morphology, distribution, B symptoms, extranodal and extracutaneous organ involvement, diffuse infiltration, subcutis involvement, significant atypia, epidermal change, epidermotropism) showed no statistical significance.

Table 2
Histopathological features of skin biopsy specimens

PTCL-NOS is a heterogeneous category of cutaneous T-cell lymphoma that does not fit into other specific categories of lymphoma4. In this study, it was difficult to rule out other specific cutaneous lymphomas in several cases. Two specimens (cases #4 and #12) showed epidermotropism, folliculotropism, and lichenoid infiltration mimicking mycosis fungoides (MF) but PTCL-NOS was diagnosed based on the clinical course (LN involvement and B symptoms in case #4) and an additional skin biopsy (case #12). Five specimens (cases #1, #5, #7, #10, #11) had panniculitis or vasculitis features mimicking subcutaneous panniculitis-like T-cell lymphoma (SPTCL) or cutaneous extranodal NK/T cell lymphoma (ENKL) and were finally diagnosed based on immunohistochemical features (case #1) and clinical course (skin involvement of systemic PTCL-NOS in cases #5, #7, #10, #11). Immunohistochemical tests showed that all of the analyzed cases were positive for CD3 and 92.3% were positive for CD4. These immunohistochemical features were similar to those reported in previous studies1, 5. Cases #10 and #12 were positive for CD20. Case #12 showed CD20 positivity in a minority of the infiltrating cells but not in the tumor cells. However, in case #10, the tumor cells co-expressed B-cell markers (CD20 and CD79a) and T-cell markers (CD3 and CD4) and gene rearrangement analysis also showed both B-cell monoclonality and T-cell monoclonality. This is a very rare case of gray zone tumor, so it is difficult to diagnose it as a specific lymphoma according to the WHO classification. This case could be interpreted as the coexistence of PTCL-NOS and diffuse large B-cell lymphoma.

The median age of patients with PTCL-NOS and cPTCL-NOS has been reported to range from 50 to 70 years2. However, case reports have been published on young adults with cPTCL-NOS6, 7, 8. The median age at diagnosis in this study was 52 years, which was younger than that in a study in a Western country but similar to a previous study in Korea1, 2. Most patients (76.9%) usually present with multifocal plaques, nodules, or tumors. No differentiation was observed in skin manifestations between primary cPTCL-NOS and secondary skin involvement in this study, compared to the previous study in which primary cPTCL-NOS showed localized cutaneous involvement1. The most common site of extranodal and extracutaneous organ involvement was BM (three cases, 23.1%) and three cases involved multi-organ involvement, including BM, the gastrointestinal tract, liver, spleen, and nasopharynx. Five patients in this study died from the disease. The median OS was longer than 17 months and ranged from 6 to 106 months. We analyzed the association between epidermotropism suspicious of MF or subcutis involvement suspicious of SPTCL or ENKL and prognosis but there was no statistically significant prognostic factor. Extranodal organ involvement, except for skin (hazard ratio [HR]=5.849; p=0.0599), and significant cellular atypia (HR=7.915; p=0.0654) almost reached significant association with poor survival. Although the significance of the prognostic factors could not be determined in this study, the significance of extranodal organ involvement and significant cellular atypia as prognostic factors needs to be verified in more cases in the future. Since the sample size of our study was small and only three patients with primary cPTCL-NOS were analyzed, our statistical power was limited. In addition, the limitations of this study include the retrospective design and referral bias to a tertiary center for advanced stage disease. cPTCL-NOS is very rare and the disease entity has not been established, therefore, more studies on cPTCL-NOS are needed to determine its precise criteria.

Notes

CONFLICTS OF INTEREST:The authors have nothing to disclose.

References

    1. Lee MH, Choi ME, Won CH, Chang SE, Lee MW, Choi JH, et al. Comparative clinicopathologic analysis of cutaneous peripheral T-cell lymphoma, not otherwise specified, according to primary tumor site. J Am Acad Dermatol 2019;80:1771–1774.
    1. Tolkachjov SN, Weenig RH, Comfere NI. Cutaneous peripheral T-cell lymphoma, not otherwise specified: a single-center prognostic analysis. J Am Acad Dermatol 2016;75:992–999.
    1. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523–531.
    1. Cerroni L. In: Skin lymphoma: the illustrated guide. 4th ed. Chichester: Wiley-Blackwell; 2014. pp. 155-162.
    1. Lee WJ, Kang HJ, Won CH, Chang SE, Choi JH, Lee MW. Secondary cutaneous peripheral T-cell lymphoma, unspecified, with generalized benign-looking dermatitis: a possibly distinct peripheral T-cell lymphoma. Int J Dermatol 2017;56:617–622.
    1. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 2013;31:1970–1976.
    1. Gupta V, Seshadri D, Khaitan BK, Nath D, Mridha AR. Peripheral T-cell lymphoma, not otherwise specified presenting with multiple tender cutaneous nodules and plaques. Indian J Dermatol Venereol Leprol 2015;81:313–315.
    1. Friedman BJ, McHargue CA, Nauss MD. Peripheral T-cell lymphoma, not otherwise specified with prominent cutaneous involvement. Indian J Dermatol Venereol Leprol 2015;81:535–537.

Metrics
Share
Tables

1 / 2

PERMALINK